Table 1. Demographic and laboratory data of patients.
| Parameters | Total (N = 185) |
|---|---|
| Age (years), mean ± SD | 54.61 ± 9.62 |
| Male sex, n (%) | 124 (67.0) |
| BMI (kg/m2), mean ± SD | 24.50 ± 4.31 |
| HCV genotype | |
| 1, n (%) | 74 (40.0) |
| 3, n (%) | 70 (37.8) |
| 6, n (%) | 41 (22.2) |
| HCV RNA (IU/mL), median (range) | 1,240,000 (5,824–25,800,000) |
| <6,000,000 IU/mL, n (%) | 160 (86.5) |
| ≥6,000,000 IU/mL, n (%) | 25 (13.5) |
| Liver fibrosis stages | |
| Significant to advanced fibrosis (F2-3), n (%) | 75 (40.5) |
| Cirrhosis (F4), n (%) | 110 (59.5) |
| CTP Class A, n (%) | 91 (49.2) |
| CTP Class B, n (%) | 19 (10.3) |
| MELD score (among cirrhosis), median (range) | 8 (6–15) |
| Prior treatment history | |
| Treatment-naïve, n (%) | 150 (81.1) |
| Treatment-experienced, n (%) | 35 (18.9) |
| Biochemical markers | |
| Total bilirubin (mg/dL), median (range) | 0.74 (0.11–2.54) |
| AST (U/L), median (range) | 73 (13–336) |
| ALT (U/L), median (range) | 76 (11–366) |
| ALP (U/L), median (range) | 88 (38–319) |
| Albumin (g/dL), median (range) | 4.30 (2.30–5.50) |
| INR, median (range) | 1.07 (0.87–2.03) |
| WBC (/mm3), median (range) | 6,190 (2,570–12,170) |
| Hemoglobin (g/dL), mean ± SD | 13.54 ± 1.70 |
| Platelet (x109/L), mean ± SD | 172.46 ± 75.04 |
| Creatinine (mg/dL), mean ± SD | 0.91 ± 0.23 |
BMI: Body mass index; HCV: Hepatitis C virus
CTP: Child-Turcotte-Pugh; MELD: Model for end-stage liver disease
AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase
INR: International normalized ratio.